IL147294A0 - USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS - Google Patents

USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Info

Publication number
IL147294A0
IL147294A0 IL14729400A IL14729400A IL147294A0 IL 147294 A0 IL147294 A0 IL 147294A0 IL 14729400 A IL14729400 A IL 14729400A IL 14729400 A IL14729400 A IL 14729400A IL 147294 A0 IL147294 A0 IL 147294A0
Authority
IL
Israel
Prior art keywords
cell migration
fviia
chemotaxis
reguating
gene expression
Prior art date
Application number
IL14729400A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL147294A0 publication Critical patent/IL147294A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL14729400A 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS IL147294A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901023 1999-07-14
US14830099P 1999-08-11 1999-08-11
DKPA199901117 1999-08-12
PCT/DK2000/000401 WO2001005353A2 (en) 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Publications (1)

Publication Number Publication Date
IL147294A0 true IL147294A0 (en) 2002-08-14

Family

ID=27221063

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14729400A IL147294A0 (en) 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Country Status (19)

Country Link
US (3) US20020193302A1 (ja)
EP (1) EP1200116B1 (ja)
JP (1) JP2003525028A (ja)
KR (1) KR100821644B1 (ja)
CN (1) CN100411684C (ja)
AT (1) ATE411041T1 (ja)
AU (1) AU5807500A (ja)
BR (1) BR0012408A (ja)
CA (1) CA2378249A1 (ja)
CZ (1) CZ200240A3 (ja)
DE (1) DE60040539D1 (ja)
ES (1) ES2316372T3 (ja)
HU (1) HUP0302052A3 (ja)
IL (1) IL147294A0 (ja)
MX (1) MXPA02000468A (ja)
NO (1) NO20020130L (ja)
PL (1) PL353035A1 (ja)
RU (1) RU2268744C2 (ja)
WO (1) WO2001005353A2 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098359A2 (en) * 2000-06-21 2001-12-27 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
DE10238429A1 (de) 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
WO2003037361A2 (en) * 2001-11-02 2003-05-08 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003065871A2 (en) * 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
JP2007501225A (ja) * 2003-08-06 2007-01-25 プライズ，ハンズ 転移防止におけるｓｉＲＮＡサイレンシングの使用
US20070207154A1 (en) * 2004-04-16 2007-09-06 Martin Friedlander Method of modulating vascularization
EA014900B1 (ru) * 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
US20100015160A1 (en) * 2007-02-21 2010-01-21 Yale University Compositions and methods for diagnosing and treating endometriosis
ES2604110T3 (es) * 2011-07-01 2017-03-03 Shiseido Company, Ltd. Activador de la producción del factor de crecimiento derivado de plaquetas-BB, y activador de la producción de células madre mesenquimatosas, estabilizador de células madre y regenerador de la dermis comprendiendo cada uno el mismo
CN109381478A (zh) * 2018-10-31 2019-02-26 青岛大学附属医院 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121028A1 (en) 1991-10-11 1993-04-15 Ulla K. E. Hedner Hemostatic composition for local hemostasis
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
CA2248549A1 (en) * 1996-03-15 1997-09-18 Munin Corporation Extracellular matrix signalling molecules
AU7907398A (en) 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US20030040481A1 (en) * 1997-07-18 2003-02-27 Lars Kongsbak Methods for modifying cell motility using a factor VIIa antagonist
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
BR0208203A (pt) 2001-03-22 2005-04-19 Novo Nordisk Healthcare Ag Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
CA2445811A1 (en) 2001-05-02 2002-11-07 Novo Nordisk A/S Modified fvii in treatment of ards
JP2004534855A (ja) 2001-07-20 2004-11-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび第ｘｉ因子ポリペプチドを含んでなる医薬組成物
EP1446147A1 (en) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
EP1446148A1 (en) 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
JP2005511599A (ja) 2001-11-09 2005-04-28 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチド及びｖ因子ポリペプチドを含む薬学的組成物
WO2003039590A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides

Also Published As

Publication number Publication date
EP1200116B1 (en) 2008-10-15
NO20020130L (no) 2002-03-13
CN100411684C (zh) 2008-08-20
MXPA02000468A (es) 2008-10-06
EP1200116A2 (en) 2002-05-02
ES2316372T3 (es) 2009-04-16
US20090036378A1 (en) 2009-02-05
CZ200240A3 (cs) 2003-04-16
CA2378249A1 (en) 2001-01-25
US20020193302A1 (en) 2002-12-19
HUP0302052A3 (en) 2005-12-28
HUP0302052A2 (hu) 2003-09-29
BR0012408A (pt) 2002-03-12
WO2001005353A3 (en) 2001-07-19
NO20020130D0 (no) 2002-01-11
JP2003525028A (ja) 2003-08-26
PL353035A1 (en) 2003-10-06
DE60040539D1 (de) 2008-11-27
US20050239708A1 (en) 2005-10-27
RU2268744C2 (ru) 2006-01-27
US7829529B2 (en) 2010-11-09
WO2001005353A2 (en) 2001-01-25
AU5807500A (en) 2001-02-05
KR100821644B1 (ko) 2008-04-11
ATE411041T1 (de) 2008-10-15
CN1460024A (zh) 2003-12-03
KR20020025194A (ko) 2002-04-03

Similar Documents

Publication Publication Date Title
EP1539234A4 (en) METHODS OF PREVENTING OR TREATING CELLULAR MALIGNITES BY ADMINISTERING CD2 ANTAGONISTS
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
IL147294A0 (en) USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGUATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS
MXPA04005790A (es) Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona.
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
MXPA05006359A (es) Tratamiento de la enfermedad a traves de inhibidores peptidos antimicrobianos.
EP1360965A4 (en) METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH A DECREASE OF THE EXPOSURE OF THE AOP-1 GENE OR AOP-1 AND MEANS FOR THE TREATMENT OF THE DISEASES
EP1663104A4 (en) PORIFERA-BASED THERAPEUTIC COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF SKIN DISEASES
IL162836A (en) Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments and pharmaceutical compositions thereof
IL164808A0 (en) Treatment of hypertesion in women receiving hormone replacement therapy
PT867184E (pt) Utilizacao de tiagabina para o tratamento de desordens do sono
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
AU2003237933A8 (en) Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
ATE275919T1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
EP1581095A4 (en) THERAPEUTIC METHODS FOR REDUCING FAT DEPOSIT AND TREATING THE DISEASES THEREOF
IL143717A0 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
AU2003230566A8 (en) Therapeutic regulation of deoxyribonuclease-1-like-3 activity
SE0100684D0 (sv) New subject-matter
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
PL373287A1 (en) New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders
ZA9711468B (en) New use of comt inhibitors